Analysis of BRCA1 germline variants (exons 5, 11 and 20) in breast cancer families from Libya.

Breast cancer (BC) is a leading cause of cancer deaths in Libyan women. BRCA1 variants differ globally due to the diversity of genetic makeup and populations history. Their distribution, prevalence, and significance in Libyans remain largely unexplored. This study investigated the characteristics and distribution of BRCA1 variants in exons 5, 11, and 20 in Libyan families with BC. Thirty-six BC patients at ≤ 45 years, between 46-50 years and with a family history of breast, ovarian, pancreatic or prostate cancer in close relatives, or with triple-negative BC, were selected from 33 unrelated families during 2018-2020 at the National Cancer Institute, Sabratha, Libya. From these 33 families, 20 women (18 BC patients and two unaffected) were screened for BRCA1 exons 5, 11 and 20 using Sanger sequencing. All families completed an epidemiology and family history questionnaire. Twenty-seven variants (26 in exon 11 and 1 in exon 20, minor allele frequency of < 0.01) were detected in 10 of 18 unrelated families (55.6%.) Among the 27 variants, 26 (96%) were heterozygous. A frameshift pathogenic variant, c.2643del, and one novel variant c.1366A>G were identified. Furthermore, seven variants with unknown clinical significance were detected: c.1158T>A, c.1346C>G, c.1174C>G, c.3630 G>T, c.3599A>T, and c.3400 G>C in exon 11, and c.5244T>A in exon 20. Six variants with conflicting pathogenicity interpretations, c. 3460T>A, c. 3572 G>A, c. 3700 G>C, c. 1246C>G, c. 1344C>G, and c. 1054 G>A, were also identified. Twelve benign/likely benign variants were identified. Rare BRCA1 variants that have not been reported in North Africa were found in Libyan patients. These findings provide preliminary insights into the BRCA1 variants that could contribute to hereditary BC risk in Libyans. Further functional, computational, and population analyses are essential to determine their significance and potential impact on BC risk, which could ultimately lead to more personalized management strategies.

[1]  A. Jemal,et al.  Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2024, CA: a cancer journal for clinicians.

[2]  Noof Al-Khal,et al.  BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer , 2024, Pharmaceuticals.

[3]  San-ming Wang.  A global perspective on the ethnic-specific BRCA variation and its implication in clinical application , 2022, Journal of the National Cancer Center.

[4]  M. Sullman,et al.  The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990–2019 , 2022, Respiratory Research.

[5]  I. Soerjomataram,et al.  Current and future burden of breast cancer: Global statistics for 2020 and 2040 , 2022, Breast.

[6]  A. Sokolenko,et al.  Strong founder effect for BRCA1 c.3629_3630delAG pathogenic variant in Chechen patients with breast or ovarian cancer , 2022, Cancer medicine.

[7]  B. Badaoui,et al.  Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa , 2021, BMC cancer.

[8]  B. Salhia,et al.  A Review of Cancer Genetics and Genomics Studies in Africa , 2021, Frontiers in Oncology.

[9]  S. Ahmed,et al.  Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers , 2021, Frontiers in Oncology.

[10]  T. Sellami-Boudawara,et al.  Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia , 2020, Journal of translational medicine.

[11]  S. Abdelhak,et al.  Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients , 2020, Frontiers in Genetics.

[12]  T. Walsh,et al.  Systematic misclassification of missense variants in BRCA1 and BRCA2 “coldspots” , 2020, Genetics in Medicine.

[13]  Lukman Thalib,et al.  Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis , 2019, BMC Cancer.

[14]  S. Abdelhak,et al.  BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report , 2019, Pathology & Oncology Research.

[15]  Gregory M. Cooper,et al.  CADD: predicting the deleteriousness of variants throughout the human genome , 2018, Nucleic Acids Res..

[16]  P. Pujol,et al.  Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer , 2016, Disease markers.

[17]  Á. Carracedo,et al.  Paternal lineages in Libya inferred from Y-chromosome haplogroups. , 2015, American journal of physical anthropology.

[18]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[19]  A. Benider,et al.  Screening of exon 11 of BRCA1 gene using the high resolution melting approach for diagnosis in Moroccan breast cancer patients , 2015, BMC Cancer.

[20]  F. Révillion,et al.  Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer. , 2014, Bulletin du cancer.

[21]  M. Balbín,et al.  Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain) , 2013, BMC Cancer.

[22]  Y. Bignon,et al.  Mutation Screening of the BRCA1 Gene in Early Onset and Familial Breast/Ovarian Cancer in Moroccan Population , 2012, International journal of medical sciences.

[23]  G. Hankins,et al.  Structure-Function of the Tumor Suppressor BRCA1 , 2012, Computational and structural biotechnology journal.

[24]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  S. Ahmed,et al.  Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population , 2011, Molecular Biology Reports.

[26]  P. V. van Diest,et al.  BRCA1 and BRCA2 germline mutation analysis in the Indonesian population , 2007, Breast Cancer Research and Treatment.